Filing Details
- Accession Number:
- 0001209191-16-112977
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-04-05 16:15:32
- Reporting Period:
- 2016-04-04
- Filing Date:
- 2016-04-05
- Accepted Time:
- 2016-04-05 16:15:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 816284 | Celgene Corp | CELG | Pharmaceutical Preparations (2834) | 222711928 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1247024 | Gilla Kaplan | C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-04-04 | 15,967 | $101.84 | 72,518 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $101.27 to $102.35, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
Billionaire Hedge Funds
